Danazol ( DrugBank: Danazol )


5 diseases
告示番号疾患名(ページ内リンク)臨床試験数
60再生不良性貧血3
63特発性血小板減少性紫斑病1
64血栓性血小板減少性紫斑病1
65原発性免疫不全症候群2
285ファンコニ貧血1

60. 再生不良性貧血


臨床試験数 : 235 薬物数 : 381 - (DrugBank : 83) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 160
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000041485
2021-01-012020-12-27Efficacy of Danazol after no response to cyclosporin in transfusion independent aplastic anemia: a prospective studyEfficacy of Danazol after no response to cyclosporin in transfusion independent aplastic anemia: a prospective study transfusion independent aplastic anemiaexperimental group:Cyclosporine combined with danazol;control group:Cyclosporine;Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical CollegeNULLRecruitingBothexperimental group:152;control group:76;Phase 4China
2ChiCTR1900027553
2019-11-282019-11-18Clinical therapies for patients in subtypes of non-severe aplastic anemiaClinical therapies for patients in subtypes of non-severe aplastic anemia non-severe aplastic anemiaearly NSAA:Cyclosporine;moderate NSAA1:Cyclosporine;moderate NSAA2:Cyclosporine+Danazol;TD NSAA:CSA+TPO+G-CSF;Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical SciencesNULLPending1885Bothearly NSAA:89;moderate NSAA1:37;moderate NSAA2:39;TD NSAA:325;China
3NCT01441037
(ClinicalTrials.gov)
July 19, 201124/9/2011Danazol for Genetic Bone Marrow and Lung DisordersMale Hormones for Telomere Related DiseasesAplastic AnemiaDrug: DanazolNational Heart, Lung, and Blood Institute (NHLBI)NULLCompleted2 YearsN/AAll27Phase 1/Phase 2United States

63. 特発性血小板減少性紫斑病


臨床試験数 : 363 薬物数 : 212 - (DrugBank : 43) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 138
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR1800016177
2018-07-012018-05-17Withdraw by the investigator Efficacy and safety of danazol combined with low-dose glucocorticoids in the treatment of refractory/recurrent primary immune thrombocytopenia: a multicenter, single arm, prospective and open clinical studyEfficacy and safety of danazol combined with low-dose glucocorticoids in the treatment of refractory/recurrent primary immune thrombocytopenia: a multicenter, single arm, prospective and open clinical study prospective and open clinical study Immune thrombocytopenic purpuraexperimental group:danazol combined with low-dose glucocorticoids ;Second Affiliated Hospital of Dalian Medical UniversityNULLTemporary halt4090Femaleexperimental group:30;N/AChina

64. 血栓性血小板減少性紫斑病


臨床試験数 : 86 薬物数 : 81 - (DrugBank : 20) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 63
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00953771
(ClinicalTrials.gov)
October 20084/8/2009Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)Phase II Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic PurpuraThrombotic Thrombocytopenic PurpuraDrug: DanazolIcahn School of Medicine at Mount SinaiBeth Israel Medical CenterTerminated18 YearsN/AAll8Phase 2United States

65. 原発性免疫不全症候群


臨床試験数 : 482 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04638517
(ClinicalTrials.gov)
September 7, 20214/11/2020The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary FibrosisThe TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary FibrosisPulmonary Fibrosis;Telomere Shortening;Telomere Disease;Dyskeratosis CongenitaDrug: Danazol;Drug: PlaceboThe University of QueenslandNULLRecruiting5 YearsN/AAll50Phase 2Australia
2NCT01001598
(ClinicalTrials.gov)
November 200922/10/2009Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis CongenitaPhase I/II Dose Escalation Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis CongenitaFanconi Anemia;Dyskeratosis CongenitaDrug: danazolBoston Children's HospitalNULLTerminated3 YearsN/AAll5Phase 1/Phase 2United States

285. ファンコニ貧血


臨床試験数 : 59 薬物数 : 118 - (DrugBank : 32) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 155
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01001598
(ClinicalTrials.gov)
November 200922/10/2009Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis CongenitaPhase I/II Dose Escalation Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis CongenitaFanconi Anemia;Dyskeratosis CongenitaDrug: danazolBoston Children's HospitalNULLTerminated3 YearsN/AAll5Phase 1/Phase 2United States